Kite Pharma (KITE) Q2 Loss Narrower than Expected, Sales Beat
August 08, 2017 at 12:02 PM EDT
While Kite’s research and development expenses shot up almost 50% from the year-ago period to $70.9 million in the reported quarter, general and administrative expenses were $41.1 million, up 73.3% from the year-ago period.
